Skip to main content
Clinical Trials/CTRI/2024/03/063700
CTRI/2024/03/063700
Not Yet Recruiting
N/A

A prospective observational study to identify the incidence of hypersensitivity and silent inactivation of PEG-Asparginase in children with acute lymphoblastic leukemia. - NI

Dr Chetan Dhamne0 sites0 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]
Sponsor
Dr Chetan Dhamne
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational

Investigators

Sponsor
Dr Chetan Dhamne

Eligibility Criteria

Inclusion Criteria

  • Children less than equal to 15 years of age with B\-ALL or T\-ALL receiving PEG asparaginaseas per ICICLE 2014 or standard of care treatment protocol at TMH.

Exclusion Criteria

  • 1\. Children who have received Asparginase as cytoreductive therapy for hyperleukocytosis will not be eligible for this study.
  • 2\. Children who receive native L asparaginase will not be eligible for the study.
  • 3\. Children who default treatment during induction of undergo induction death will be taken off study.

Outcomes

Primary Outcomes

Not specified

Similar Trials